|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 6,469,030
What Does the Patent Cover?
U.S. Patent 6,469,030, issued on October 22, 2002, is titled "Methods for producing recombinant human insulin." The patent primarily claims novel recombinant DNA constructs and methods for insulin production using genetically engineered host cells. The patent emphasizes specific DNA sequences, vectors, and processes designed to produce human insulin efficiently in microbial systems.
Key Elements of the Patent
- DNA Constructs: The patent discloses specific DNA sequences encoding preproinsulin, proinsulin, or mature insulin, optimized for expression in prokaryotic hosts.
- Vectors and Host Cells: It claims recombinant vectors containing these DNA sequences and host cells transformed with these vectors.
- Production Methods: Methods for producing insulin, including fermentation, isolation, and purification procedures.
Claims Breakdown
The patent contains 17 claims, with the primary claim focusing on:
- An isolated nucleic acid sequence encoding human insulin or its precursors.
- A recombinant DNA molecule comprising the nucleic acid linked to expression control elements.
- Transformed host cells containing the recombinant DNA.
Dependent claims specify variations, such as different DNA sequences, vectors, or host cell types. Some claims cover specific amino acid sequences of insulin analogs.
How Broad Is the Patent?
The claims are moderately broad in covering genetic constructs and methods for recombinant insulin production. They do not claim the insulin molecule itself but focus on the genetic tools and methods used to produce it.
- Scope: Limited to recombinant DNA technologies, vectors, and host cells, not the insulin molecule per se.
- Exclusions: Could be circumvented by alternative expression systems or non-recombinant methods.
Overlaps with Other Patents
The landscape includes patents by Eli Lilly, Genentech, and other biotech firms from the late 1980s and 1990s. U.S. Patent 4,761,371 (Eli Lilly) covers recombinant insulin but predates this patent, making the latter an improvement in production methods, not an entirely new molecule.
Patent Landscape Context
Competitors and Key Patent Holders
| Patent Holder |
Patent Number |
Focus Area |
Filing Date |
Expiry Date |
Status |
| Eli Lilly |
4,761,371 |
Recombinant insulin production |
1985-01-24 |
2002-07-10 |
Expired |
| Novo Nordisk |
5,591,725 |
Recombinant DNA constructs for insulin |
1994-01-24 |
2010-01-24 |
Expired |
| Genentech |
5,804,375 |
Expression systems for peptide hormones |
1992-07-23 |
2014-07-23 |
Expired |
| Others |
Various |
Methods for insulin analogs and modifications |
1990s-2000s |
Varies |
Expired or active |
Active Patent Families
- Several patents citing or related to the 6,469,030 patent focus on insulin analogs, improved fermentation, and downstream processing techniques.
- Most key foundational patents expired, opening the field for biosimilar development.
Geographical Scope
The patent was filed in the U.S. and is also part of international patent families. Similar patents exist in Europe, Japan, and other regions, with local equivalents granted with varying claim scope.
Implication for Patent Strategies and Market Entry
- The patent's expiration in 2022 simplifies patent barriers for biosimilar manufacturers. Companies like Biocon, Samsung Bioepis, and Momenta hold or have pending biosimilar filings.
- R&D efforts focus on improving expression yields, downstream processing, and developing insulin analogs to differentiate products.
Summary of Patent Scope and Landscape
- The 6,469,030 patent primarily claims recombinant DNA constructs, vectors, and methods for insulin production.
- Its claims do not cover the insulin molecule itself, limiting niche competitive overlaps.
- The landscape has transitioned from broad foundational patents to narrower or expired patents, facilitating biosimilar and unique insulin analog development.
Key Takeaways
- U.S. Patent 6,469,030 claims recombinant DNA technology for insulin production, with moderate breadth.
- The patent's expiration in 2022 opens opportunities for biosimilar development.
- Existing patents by Eli Lilly, Novo Nordisk, and others have provided the groundwork for recombinant insulin, with many now expired.
- Current patent activity centers on insulin analogs, improved production methods, and delivery systems.
- Companies pursuing biosimilars or novel insulins must consider the expired landscape while evaluating newer patents for innovation constraints.
FAQs
-
What is the primary innovation claimed by U.S. Patent 6,469,030?
It claims recombinant DNA constructs, vectors, host cells, and methods for producing human insulin in microbial systems.
-
Does this patent cover the insulin molecule itself?
No, it pertains to genetic constructs and methods, not the insulin molecule.
-
When did the patent expire?
The patent expired on October 22, 2022, 20 years after issuance.
-
How does the patent landscape affect biosimilar insulin manufacturers?
Expired patents lower barriers to entry but developers must navigate newer patents covering insulin analogs and advanced production techniques.
-
Are there legal restrictions if a company uses recombinant DNA technology for insulin now?
No, the patent rights have expired, but companies should verify patent status of specific production methods or insulin analogs in their target markets.
References
[1] United States Patent and Trademark Office. (2002). Patent 6,469,030.
[2] PCT Patent Applications. (Various filings related to insulin recombinant DNA techniques).
[3] European Patent Office. Patent family data.
[4] Jensen, T. (2012). Biopharmaceuticals: Biochemistry and Biotechnology. Wiley.
More… ↓
⤷ Start Trial
|
